34 terminated. 34 Phase 2, 13 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Terminated 34 |
| Phase 1 | 13 | Terminated 13 |
Follow Small Cell Lung Cancer: new trials by email Literature Review of Small Cell Lung Cancer trials Research Report on Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer XmAb18087, XmAb18087 ± Pembrolizumab - Merkel Cell Carcinoma, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Xencor, Inc. | 4 | 2021-05-10 | 2023-04-20 |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2 - Metastatic Solid Tumor, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Hutchmed | 87 | 2021-03-05 | 2025-05-08 |
| Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer APG-1252, Paclitaxel - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Ascentage Pharma Group Inc. | 28 | 2020-08-20 | 2022-07-12 |
| A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy PLM60 - Small Cell Lung Cancer | Phase 2 | Terminated | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 45 | 2020-06-18 | 2024-03-07 |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors ladiratuzumab vedotin, pembrolizumab - Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous | Phase 2 | Terminated | Seagen Inc. | 205 | 2019-10-09 | 2025-03-10 |
| DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer DS-3201b, irinotecan - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 22 | 2019-03-15 | 2024-10-10 |
| [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) [68Ga]-NeoBOMB1 - Breast Cancer, Prostate Cancer | Phase 2 | Terminated | Advanced Accelerator Applications | 19 | 2018-07-03 | 2020-10-23 |
| Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) Nivolumab, Ipilimumab, Dendritic Cell based p53 Vaccine - Small Cell Lung Cancer, Lung Cancer | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 14 | 2018-03-15 | 2023-03-30 |
| AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] AZD2811 - Small Cell Lung Cancer | Phase 2 | Terminated | Samsung Medical Center | 15 | 2017-12-01 | 2018-11-27 |
| Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification vistusertib (AZD2014) - Small Cell Lung Cancer | Phase 2 | Terminated | Samsung Medical Center | 4 | 2017-08-02 | 2018-09-20 |
| Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer Topotecan, Pembrolizumab - Small Cell Lung Cancer | Phase 2 | Terminated | Alliance Foundation Trials, LLC. | 9 | 2017-05-20 | 2023-02-15 |
| A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer Ipilimumab, Nivolumab, Rovalpituzumab tesirine - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | AbbVie | 42 | 2017-03-30 | 2020-07-17 |
| STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC) Gemcitabine, Carboplatin, Etoposide - Small Cell Lung Cancer | Phase 2 | Terminated | University College, London | 72 | 2017-03-14 | 2021-03-18 |
| Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation AZD1775 - Small Cell Lung Cancer | Phase 2 | Terminated | Samsung Medical Center | 7 | 2016-06-07 | 2018-09-20 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 45 | 2016-05-09 | 2026-08-13 |
| Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Pembrolizumab, Gemcitabine, Docetaxel - Advanced Cancer, Breast Cancer | Phase 1 / Phase 2 | Terminated | Western Regional Medical Center | 81 | 2014-12-01 | 2018-07-02 |
| A Phase I/II Study of Ganetespib in Combination With Doxorubicin Ganetespib, Doxorubicin - Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Georgetown University | 11 | 2014-10-01 | 2018-04-23 |
| A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Lucitanib - Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | Phase 2 | Terminated | Clovis Oncology, Inc. | 18 | 2014-04-01 | 2019-07-29 |
| Hair-sparing Whole Brain Radiotherapy Whole brain radiotherapy with volumetric arc therapy - Brain Metastases, Small Cell Lung Cancer | Phase 2 | Terminated | University Hospital, Ghent | 29 | 2013-01-01 | 2015-06-04 |
Showing 20 of 34. Sign in to see all of them.
Small Cell Lung Carcinoma (34) · Lung Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (5) · Sarcoma (4) · Breast Neoplasms (3) · Colorectal Neoplasms (3) · Prostatic Neoplasms (3) · Glioblastoma (2) · Melanoma (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Uterine Cervical Neoplasms (2) · Brain Neoplasms (1)
Bronchial Neoplasms (34) · Carcinoma, Bronchogenic (34) · Neoplasms by Site (34) · Respiratory Tract Diseases (34) · Respiratory Tract Neoplasms (34) · Thoracic Neoplasms (34) · Lung Diseases (33) · Neoplasms (32) · Lung Neoplasms (27) · Neoplasms by Histologic Type (8) · Carcinoma (7) · Neoplasms, Glandular and Epithelial (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (5)
Carboplatin (6) · Etoposide (4) · Pemetrexed (4) · Albumin-Bound Paclitaxel (3) · Cisplatin (3) · Irinotecan (3) · pembrolizumab (3) · Gemcitabine (2) · Ipilimumab (2) · Nivolumab (2) · Paclitaxel (2) · Topotecan (2) · Vorinostat (2) · 130-nm albumin-bound paclitaxel (1) · ADI PEG20 (1)
Eli Lilly and Company (3) · Samsung Medical Center (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · AbbVie (1) · Advanced Accelerator Applications (1) · Alliance Foundation Trials, LLC. (1) · Armando Santoro, MD (1) · Ascentage Pharma Group Inc. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Clovis Oncology, Inc. (1) · Georgetown University (1) · Hoosier Cancer Research Network (1) · Hutchmed (1) · ImmunoGen, Inc. (1)
United States (20) · United Kingdom (6) · Italy (5) · South Korea (5) · Spain (5) · Belgium (3) · France (3) · Germany (3) · Australia (2) · Taiwan (2) · Austria (1) · Canada (1) · China (1) · Netherlands (1) · Poland (1)
Thomas Stinchcombe, MD (2) · Alberto Chiappori, M.D. (1) · Anish Thomas, M.D. (1) · Armando Santoro, MD (1) · Ashish Sangal, MD (1) · Benjamin Thompson, MD, PhD (1) · Chandra P Belani, MD (1) · Charles Rudin, MD, PhD (1) · Duncan I Jodrell (1) · Giuseppe Giaccone, MD PhD (1)
PMID 19096313, PMID 25616430, PMID 29119276, PMID 29594044, PMID 32897402, PMID 33775123, PMID 35844029, PMID 42820295
2008 (1), 2016 (1), 2017 (1)